
Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown
Published: Aug. 11, 2023
Abstract The use of oncolytic viruses as a gene therapy vector is an area active biomedical research, particularly in the context cancer treatment. However, actual therapeutic success this approach to tumor elimination remains limited. As such, present study was developed with goal simultaneously enhancing antitumor efficacy and local immune response by combining Ad-GD55 adenovirus antibody specific for TIM-3 checkpoint molecule (α-TIM-3). resultant Ad-GD55-α-Tim-3 capable inducing α-TIM-3 expression within hepatoma cells upon infection, exhibited inhibitory superior that when used treat these together induction enhanced intracellular immunity. In vivo experiments revealed Ad-GD55-α-TIM-3 administration sufficient inhibit growth engage more robust simulated microenvironment. may represent viable treatment hepatocellular carcinoma.
Language: Английский